Hepatocellular carcinoma in patients with chronic kidney disease

被引:18
作者
Lee, Chern-Horng [1 ,2 ]
Hsieh, Sen-Yung [1 ,3 ]
Lin, Ja-Liang [1 ,4 ]
Liu, Maw-Sen [1 ,2 ]
Yen, Tzung-Hai [1 ,4 ]
机构
[1] Chang Gung Univ, Coll Med, Tao Yuan 333, Taiwan
[2] Chang Gung Mem Hosp, Dept Gen Internal Med & Geriatr, Linkou 333, Taiwan
[3] Chang Gung Mem Hosp, Liver Res Unit, Tao Yuan 333, Taiwan
[4] Chang Gung Mem Hosp, Dept Nephrol, Taipei 105, Taiwan
关键词
Hepatocellular carcinoma; Hepatitis B virus; Hepatitis C virus; Chronic kidney disease; End-stage renal disease; STAGE RENAL-DISEASE; HEPATITIS-C VIRUS; TRANSITIONAL-CELL CARCINOMA; CANCER-SPECIFIC MORTALITY; B-VIRUS; MAINTENANCE HEMODIALYSIS; LIVER RESECTION; ASSOCIATION; DIALYSIS; FAILURE;
D O I
10.3748/wjg.v19.i16.2466
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To investigate outcomes of hepatocellular carcinomas (HCCs) in patients with chronic kidney disease (CKD). METHODS: Four hundred and forty patients referred between 2000 and 2002 for management of HCCs were categorized according to their CKD stage, i.e., estimated glomerular filtration rate (eGFR) > 90 (stage 1), 60-90 (stage 2), 30-60 (stage 3), 15-30 (stage 4), and < 15 (stage 5) mL/min per 1.73 m(2), respectively. Demographic, clinical and laboratory data were collected and mortality rates and cause of mortality were analyzed. The mortality data were examined with Kaplan-meier method and the significance was tested using a log-rank test. An initial univariate Cox regression analysis was performed to compare the frequency of possible risk factors associated with mortality. To control for possible confounding factors, a multivariate Cox regression analysis (stepwise backward approach) was performed to analyze those factors that were significant in univariate models (P < 0.05) and met the assumptions of a proportional hazard model. RESULTS: Most HCC patients with CKD were elderly, with mean age of diagnosis of 60.6 +/- 11.9 years, and mostly male (74.8%). Hepatitis B, C and B and C co-infection virus were positive in 61.6%, 45.7% and 14.1% of the patients, respectively. It was found that patients with stages 4 and 5 CKD were not only older (P = 0.001), but also had higher hepatitis C virus carrier rate (P = 0.001), lower serum albumin level (P = 0.001), lower platelet count (P = 0.037), longer prothrombin time (P = 0.001) as well as higher proportions of advanced cirrhosis (P = 0.002) and HCCs (P = 0.001) than patients with stages 1 and 2 CKD. At the end of analysis, 162 (36.9%) patients had died. Kaplan-Meier analysis revealed that patients with stages 4 and 5 CKD suffered lower cumulative survival than stages 1 and 2 CKD (log-rank test, chi(2) = 11.764, P = 0.003). In a multivariate Cox-regression model, it was confirmed that CKD stage [odds ratio (OR) = 1.988, 95% CI: 1.012-3.906, P = 0.046)], liver cirrhosis stage (OR = 3.571, 95% CI: 1.590-8.000, P = 0.002) and serum albumin level (OR = 0.657, 95% CI: 0.491-0.878, P = 0.005) were significant predictors for mortality in this population. CONCLUSION: HCC patients with stages 4 and 5 CKD had inferior survival than stages 1 and 2 CKD. This warrants further studies. (C) 2013 Baishideng. All rights reserved.
引用
收藏
页码:2466 / 2472
页数:7
相关论文
共 50 条
[21]   Effect of smoking on survival of patients with hepatocellular carcinoma [J].
Kolly, Philippe ;
Knopfli, Marina ;
Dufour, Jean-Francois .
LIVER INTERNATIONAL, 2017, 37 (11) :1682-1687
[22]   Hepatitis B virus infection as a risk factor for chronic kidney disease [J].
Fabrizi, Fabrizio ;
Cerutti, Roberta ;
Ridruejo, Ezequiel .
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (09) :867-874
[23]   Constipation in Patients With Chronic Kidney Disease [J].
Cha, Ra Ri ;
Park, Seon-Young ;
Camilleri, Michael .
JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2023, 29 (04) :428-435
[24]   Should we change the treatment plan in early hepatocellular carcinoma with chronic kidney disease? [J].
Chao, Wu-Po ;
Chai, Shion-Wei ;
Chiang, Po-Hsing ;
Chou, Ta-Chun ;
Chen, Yi-Chan ;
Soong, Ruey-Shyang .
BMC SURGERY, 2023, 23 (01)
[25]   Should we change the treatment plan in early hepatocellular carcinoma with chronic kidney disease? [J].
Wu-Po Chao ;
Shion-Wei Chai ;
Po-Hsing Chiang ;
Ta-Chun Chou ;
Yi-Chan Chen ;
Ruey-Shyang Soong .
BMC Surgery, 23
[26]   Autoantibodies to survivin in patients with chronic hepatitis and hepatocellular carcinoma [J].
Yagihashi, A ;
Asanuma, K ;
Kobayashi, D ;
Tsuji, N ;
Torigoe, T ;
Sato, N ;
Watanabe, N .
AUTOIMMUNITY, 2005, 38 (06) :445-448
[27]   Opioid Use in Chronic Pain Patients with Chronic Kidney Disease: A Systematic Review [J].
Nagar, Vittal R. ;
Birthi, Pravardhan ;
Salles, Sara ;
Sloan, Paul A. .
PAIN MEDICINE, 2017, 18 (08) :1416-1449
[28]   Hepatocellular carcinoma in patients with chronic hepatitis C virus infection without cirrhosis [J].
Nash, Kathryn L. ;
Woodall, Tracy ;
Brown, Ashley S. M. ;
Davies, Susan E. ;
Alexander, Graeme J. M. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (32) :4061-4065
[29]   Glycemic load in relation to hepatocellular carcinoma among patients with chronic hepatitis infection [J].
Lagiou, P. ;
Rossi, M. ;
Tzonou, A. ;
Georgila, C. ;
Trichopoulos, D. ;
La Vecchia, C. .
ANNALS OF ONCOLOGY, 2009, 20 (10) :1741-1745
[30]   Hepatocellular carcinoma in patients with chronic renal disease: Challenges of interventional treatment [J].
Sarno, Gerardo ;
Montalti, Roberto ;
Giglio, Mariano Cesare ;
Rompianesi, Gianluca ;
Tomassini, Federico ;
Scarpellini, Emidio ;
De Simone, Giuseppe ;
De Palma, Giovanni Domenico ;
Troisi, Roberto Ivan .
SURGICAL ONCOLOGY-OXFORD, 2021, 36 :42-50